Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 11/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7727914 | 0.99 | NISCH (0.52) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7736812 | 0.87 | NISCH (0.52) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7738742 | 0.87 | LMNA (0.52) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7736342 | 0.86 | NISCH (0.53) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7736197 | 0.81 | NISCH (0.58) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| SCHEMBL6824704 | 0.81 | NISCH (0.51) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7736199 | 0.80 | NISCH (0.50) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7736305 | 0.78 | NISCH (0.48) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7736789 | 0.78 | NISCH (0.53) | NISCHMAOAMAOBALDH1A1CYP1A2 | |
| SCHEMBL6826787 | 0.77 | NISCH (0.58) | NISCHMAOAMAOBALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | claimed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | claimed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | claimed |
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | NISCH 277/4885MAOA 3888/4885MAOB 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.